Incidence of cytological abnormalities within 24 months of a normal cervical smear in Soweto, South Africa.
Abstract: Background. A screening programme for cervical cancer has been implemented in South Africa (SA) with intervals of 10 years after a normal cytological result. There are no studies that evaluate repeat screening at a shorter interval in SA.

Objectives. (i) To find the incidence of cytological abnormalities on a repeat test after a report of normal cytology or an inadequate Pap smear; and (ii) to explore the factors associated with an abnormal cytology on repeat testing.

Methods. This was a secondary data analysis of a randomised controlled trial of diaphragm, lubricant gel and condoms v. condoms in the prevention of HIV infection. HIV-negative women were recruited between November 2003 and December 2005, with a normal Pap smear at entry. Observation time was from the first Pap smear to the date of the repeat Pap smear. Explanatory variables used were baseline, excepting any new HIV infection.

Results. The incidence of cytological abnormalities was 6.48% yearly in women with a previously normal Pap smear and 11.71% yearly in women with an inadequate smear result (p=0.03). The incidence of high-grade squamous intra-epithelial lesions (HSILs) was <0.5%. Factors associated with abnormal cytology were a history of ectopic pregnancy (odds ratio (OR) 9.25; confidence interval (CI) 1.78-48.02; p=0.01), number of male partners (OR 1.12; CI 1.03-1.22; p=0.01), history of vaginal discharge (OR 13.95; CI 1.18-164.47; p=0.04), and incident HIV infection (OR 6.56; CI 1.14-38.16; p=0.04).

Conclusion. The incidence of HSILs is low in the first 2 years after a normal or inadequate Pap smear, even in a setting with a high prevalence of cytological abnormalities.

S Afr Med J 2013;103(1):34-39. DOI:10.7196/SAMJ.6124
Article Type: Clinical report
Subject: HIV infection (Risk factors)
HIV infection (Development and progression)
HIV (Viruses) (Risk factors)
HIV (Viruses) (Development and progression)
Infection (Risk factors)
Infection (Development and progression)
Papillomavirus infections (Risk factors)
Papillomavirus infections (Development and progression)
Sexually transmitted diseases (Risk factors)
Sexually transmitted diseases (Development and progression)
Cervical cancer (Risk factors)
Cervical cancer (Development and progression)
Cancer (Prevention)
Women (Health aspects)
Cancer (Research)
Cancer (Diagnosis)
Lubrication and lubricants
HIV testing
Medical tests
Condoms
Oncology, Experimental
Enzyme-linked immunosorbent assay
Authors: Adam, Y.
McIntyre, J.A.
de Bruyn, G.
Pub Date: 01/01/2013
Publication: Name: South African Medical Journal Publisher: South African Medical Association Audience: Academic Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2013 South African Medical Association ISSN: 0256-9574
Issue: Date: Jan, 2013 Source Volume: 103 Source Issue: 1
Product: Product Code: 2992000 Lube Oil & Greases; 3069770 Prophylactics & Diaphragms; 8000220 Cancer & Cell R&D NAICS Code: 324191 Petroleum Lubricating Oil and Grease Manufacturing; 326299 All Other Rubber Product Manufacturing; 54171 Research and Development in the Physical, Engineering, and Life Sciences SIC Code: 2992 Lubricating oils and greases; 3069 Fabricated rubber products, not elsewhere classified; 8731 Commercial physical research; 8733 Noncommercial research organizations
Accession Number: 312828770
Full Text: Population-based screening using Papanicolaou (Pap) smears and treatment programmes of pre-malignant lesions of the cervix has significantly reduced the morbidity and mortality associated with cervical cancer. In developed countries, associated deaths have been reduced by 45-80%. (1-3)

Screening practices differ between countries according to local experience and cost. In the UK, systematic screening was introduced in 1988, and reduced death by cervical cancer by 50%. This programme's screening interval has been 3-5 years, but its success has been attributed to its coverage, reaching about 80.6% of eligible women by 2004. (2)

South Africa (SA) is a middle-income country with many competing health needs and a poorly developed infrastructure for colposcopy services. The country established a cervical cancer prevention programme in 2001, under which women are offered 3 Pap smears in a lifetime starting at age 30 years. However, if the first Pap smear is performed after the age of 55 years and is normal, only one Pap smear will be performed, while women in whom the cytology is reported as inadequate are re-screened. Furthermore, women with any gynaecological complaint should receive a smear as part of their gynaecological examination irrespective of their screening history. (4)

Cytology has a false-negative rate of 15-30%. (5,6) In a South African study, 10% of cervical cancer cases occurred in women who had been screened, but at least 5 years previously. More than 50% occurred in women who had never been screened.7 Prospective studies have not evaluated screening intervals >5 years between Pap smears.

Between 2004 and 2006 in Soweto, Johannesburg, a trial investigated the use of the diaphragm in preventing HIV infection, and also offered a Pap smear at the enrolment visit and again at the end of the trial.8 These data allowed us to assess the incidence of abnormal cytology after a normal or inadequate Pap smear in a setting with a high prevalence of cervical abnormalities. (7) We aimed to determine the proportion of women who developed an abnormal Pap smear within 24 months of a normal Pap smear, in a cohort of women in Soweto. Risk factors associated with an incident abnormal Pap smear were explored.

Methods

Between November 2003 and December 2005, the Soweto site of the Methods for Improving Reproductive Health in Africa (MIRA) trial recruited 1 028 women from the surrounding community and district clinics (ClinicalTrials.gov number NCT00211459). This study is a secondary analysis of data from this randomised open-label trial, which compared the effectiveness of using condoms alone to using a combination of condoms, the latex diaphragm (Ortho-McNeil Pharmaceutical, Raritan, NJ, USA) and a lubricant gel (Replens, Lil' Drug Store Products, Cedar Rapids, IA, USA) for preventing HIV infection in women. Participants received an HIV prevention package that included HIV/sexually transmitted infection (STI) pre- and post-test counselling, treatment of treatable laboratory-diagnosed STIs, condom promotion and risk-reduction counselling.

Participants were HIV-uninfected, sexually active women, aged 18-49 years. Eligible subjects had a cervix, consented to be treated for any treatable STI and did not desire a pregnancy at the time. Participants were monitored quarterly for a period of 12-24 months for HIV infection and other STIs.

Interviews conducted at enrolment were used to obtain demographic information and medical and gynaecological history. Women also underwent a pelvic examination at the first visit and all were offered a Pap smear (protocol required that all women who had not had a Pap smear in the preceding 12 months be offered a Pap smear). Women were also offered a Pap smear at exit.

The Pap smears were conventional smears performed by nurse clinicians, and reported on by the SA National Health Laboratory Service (NHLS) cytopathology department. This accredited laboratory has stringent internal and external quality control. The recommendations for management of Pap smear abnormalities stipulated that any Pap smear without an endo- or ectocervical component was inadequate and had to be repeated, even when the descriptive diagnosis was 'within normal limits'. Any Pap report of low-grade squamous intra-epithelial lesions or atypical squamous cells of undetermined significance (ASCUS) was repeated in 6 months. Meanwhile, reports of high-grade squamous intra-epithelial lesions (HSILs) or atypical glandular cells were referred to the Colposcopy Clinic at Chris Hani Baragwanath Academic Hospital for further management.

Only STI tests at enrolment (prevalence data) and incident HIV test results were used. Polymerase chain reaction (PCR) testing was performed for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis. A blood test was provided at enrolment and at exit for herpes simplex virus 2 (Focus HSV2 enzyme-linked immunosorbent assay (ELISA)) and syphilis (rapid plasma reagin (RPR) and Treponema pallidum haemagglutinin (TPHA)). A finger-prick blood sample or venous puncture was obtained for rapid HIV-1/2 testing (Oraquick and Determine tests).

Women with equivocal results underwent confirmatory laboratory ELISA testing. Participants were notified about the HIV result and post-test counselling was provided to both HIV-positive and -negative women.

We conducted a secondary analysis of the MIRA trial data. Pap smear results were coded as normal/inadequate or abnormal (ASCUS, LSIL, HSIL or more severe). We defined observation time as the date from the first Pap smear (enrolment) to the date of the repeat Pap smear. All explanatory variables used were baseline variables, except new HIV infection.

The data analysis was performed using STATA statistical software (version 10). Using standard statistical methods, we compared the distributions of explanatory variables among women who continued to have a normal Pap smear v. those who developed abnormal cytology.

We performed a bivariate analysis using a logistic regression to determine factors associated with the outcome. We entered all variables found to be significant in bivariate testing (p<0.2) and used a backward selection procedure to arrive at a final multivariate model.

To compare the risk of an abnormal Pap smear in those who had a normal Pap smear at baseline with those who had an inadequate Pap smear at baseline, we used standard methods for time-to-event data to determine time to abnormal cervical cytology.

The Human Research Ethics Committee (Medical) of the University of the Witwatersrand approved the study protocol for the MIRA trial (M031111) and granted ethical clearance for the use of the data in this secondary analysis (M090676).

Results

Among those eligible for the study, 850 women underwent a repeat Pap smear; 97 (11.41%) had an abnormal Pap smear at entry and were excluded (Fig. 1). These abnormalities were comprised of ASCUS (31 cases; 3.65%), LSIL (51 cases; 6%) and HSIL (15 cases; 1.76%).

The incidence of cytological abnormalities in this group of women (baseline Pap normal or inadequate) was 7.33% per annum. The incidence of cytological abnormalities was 6.48 % in women with a previously normal Pap and 11.71% in women with an inadequate smear result. Fig. 2 depicts the risk of having an abnormal Pap smear. The median follow-up time was 297 days (interquartile range (IQR) 182-455).

The log-rank test for equality of survivor function indicates that there is a statistically significant difference in the risk of a cytological abnormality after a normal Pap smear when compared with an inadequate one (p=0.03).

Of both the normal and inadequate Pap smears <0.5% had an HSIL reported on their subsequent Pap smear and the rest of the abnormalities were LSIL and ASCUS (Table 1).

[FIGURE 1 OMITTED]

[FIGURE 2 OMITTED]

The subjects' median age was 28 years (IQR 22-35) and the median number of years they had been educated was 12 (IQR 10 12). Participants were not asked about smoking or alcohol use.

Types of contraception being used at the time of enrolment were: combined oral contraception (n=58; 7.70%); injectable hormonal contraception; (n=223; 29.61%); progestogen-only pills (n=20; 2.66%); intra-uterine contraceptive device (n=7; 0.93%); and withdrawal or natural methods (17; 2.26%).

The association between condom usage and the incidence of an abnormal Pap smear was contradictory: while there where fewer women with cervical abnormalities in those randomised to the control group (condoms only), there was no association in women who said they used condoms at the last intercourse or were currently using them (Table 2).

The median parity in this group was 2 (IQR 1-3), with a range of 0-7. The difference in pregnancy history (live births, vaginal deliveries, miscarriages and abortions) in women who had a subsequent normal or abnormal Pap smear was not significant. An ectopic pregnancy in the past was associated with an abnormal Pap smear, but this association was not statistically significant (4 (4.82%) v. 10 (1.61%); p=0.7).

The mean age of first intercourse was 17.58 years (standard deviation (SD) [+ or -]2.12; range 11-27). There was no statistical difference in having a subsequent abnormal Pap smear in women who had had an earlier sexual debut (p = 0.24) or in women who had had sex in exchange for money (p = 0.11). Women with an increased number of sexual partners were more likely to have an abnormal Pap smear on repeat testing (mean 4.85 (SD [+ or -]3.40) v. mean 3.48 (SD [+ or -]2.73); p=0.00). The trial excluded women who performed <3 coital acts in the month; therefore, it was not meaningful to assess difference by coital frequency. Age at first intercourse was not reflected in any statistical difference in the outcome (Table 3).

Table 4 shows the association between the risk of developing an abnormal cytology on Pap smear, and whether subjects had a history suggestive of an STI in the preceding 3 months or alternatively confirmatory tests of STIs. A history of a vaginal discharge in the preceding 3 months, or symptoms of an STI, were important differences between those who did and those who did not develop cytological abnormalities. Clinical findings for STIs were discovered on examination, rather than following complaints from the women, as could be expected in a research setting.

There were no statistical differences in incident cervical cytological abnormalities among women with objective evidence of an STI at baseline and no infection (Table 4). Incident STIs such as chlamydia (n=32; 4.25%), gonorrhoea (n=13; 1.73%) and trichomonas (n=38; 5.05%) were not associated with an increase in cytological abnormalities.

Incident HIV infection was associated with a 6-fold increase in the risk of an abnormal Pap smear. An abnormal discharge in the last 3 months and having had an ectopic pregnancy at any time also increased the risk. Having used a condom after the last intercourse had no effect, but being allocated to the control (condom) arm of the study reduced the risk by approximately 58% (Table 5).

Discussion

The SA cervical screening guidelines predict a reduction of cervical cancer of between 64-70% with a screening interval of 10 years.4,9 An evaluation of screening intervals shows that screening is associated with a reduced incidence of cervical cancer, ranging from 84% with 5-year intervals to 94% when the screening was performed every 2 years, in both cases in women aged 35-64 years.10

We used the presence of any cytological abnormality as an outcome measure, because this would mean that the particular woman is at risk of cervical cancer, albeit with a different degree of risk. Of note was a low incidence of HSILs, which is the threshold for treatment in our setting: 0.46% and 0.37% in the inadequate and adequate Pap smear groups, respectively. The prevalence of HSILs in women who were recruited for the study was 1.76%.

The Australian National Health and Medical Research Council Guidelines recommend that all pathologists report normal Pap smear results with a recommendation that the next Pap smear is due in 2 years, irrespective of the presence or absence of endocervical component or of reactive change. (11)

There was no testing for human papillomavirus (HPV) in our study; if we use abnormal cytology as a proxy for HPV infection then its incidence is much higher than that of herpes or HIV. In women with a normal Pap smear at recruitment, the incidence of herpes was 3.32%, HIV 1.33% and HPV (using abnormal Pap smears as a marker) at least 7.33%. An HIV infection incidence of 1.33% is much lower than in the MIRA study, where it was 4%8 (as explained in Fig. 1, we excluded all women with an abnormal Pap smear at baseline).

HPV infection was not shown to be a risk factor for HIV infection in a Zimbabwean study, (12) but because women with dysplasia on their entry Pap were excluded from this study it may be that dysplastic cervical epithelium accounted for the higher rate of HIV infection in the parent study. (8)

Condom use reduces HPV transmission, (13) persistence (14) and seropositivity.15 A history of male condom usage was protective against acquiring an abnormal Pap smear in this study, but this was not statistically significant. Assignment to the condoms-only arm of the MIRA trial, however, was associated with a 50% lower risk of an abnormal Pap smear than assignment to the diaphragm arm (p=0.01).

Asking subjects about 'condom use at last intercourse' is considered a good way to assess use because it reduces recall bias. However, in this analysis this criterion did not differ between the two groups, even on stratifying by randomisation. The prevalence of female condom use was low in this group of women and was discouraged by the researchers owing to probable problems with fitting of the diaphragm for women in the intervention arm (diaphragm, lubricant and condoms).

A limitation of the study was that only women who agreed to be treated for an STI that had been detected by a laboratory test were eligible for inclusion. The the rate of cytological abnormality may also differ in women symptomatic for STI presenting at a gynaecological clinic. The study sample was too small for stratifying into different age categories, and to fully evaluate risk factors. Pap smears have a poor sensitivity and therefore we were not able to evaluate sensitivity. Although Pap smear screening has a high specificity, only colposcopically directed biopsies can confirm the exact grade of the lesion. The study numbers were also too small for us to use the presence of HSILs as an outcome measure.

The study's strengths included that its population comprised sexually active women from Soweto who had a high prevalence of cervical cancer, and loss to follow-up was approximately 7%.

The results of this study suggest that it would be safe for the next Pap to be delayed for at least 1 year even in women with an inadequate Pap smear result.

The lower incidence of HIV warrants further study on whether cervical dysplasia, and not just HPV infection, is an independent risk factor for HIV infection.

Disclosure. This paper was part of a dissertation submitted for an MSc degree (Epidemiology & Biostatistics) by Y Adam to the University of the Witwatersrand.

Accepted 20 August 2012.

References

(1.) Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003;89:88-93. [http:dx.doi.org/10.1038/sj.bjc.6600974;

(2.) Peto J, Gilham C, Fletcher O, Matthews F. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004;364(9430):249-256. [http://dx.doi.org/10.1016/S0140-6736(04)16674-9;

(3.) New Zealand Health Information Service. Mortality and Demographic Data 2000. Wellington: Ministry of Health, 2004.

(4.) National Guidelines for Cervical Cancer Screening in South Africa 2000. http://www.doh.gov.za/docs/ facts-f.html (accessed 13 May 2008).

(5.) McLachlin C, Mai V, Murphy J, et al. Ontario cervical cancer screening clinical practice guidelines. J Obstet Gynaecol Can. 2007;29(4):344-353.

(6.) Saslow D, Runowicz C, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52(6):342-362.

(7.) Fonn S, Bloch B, Mabina M, et al. Prevalence of pre-cancerous lesions and cervical cancer in South Africa-a multicentre study. S Afr Med J 2002;92(2):148-156.

(8.) Padian NS, Van der Straten A, Ramjee G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007;370(9583):251 261. [http://dx.doi.org/10.1016%2FS0140-6736(07)60950-7;.

(9.) Hoffman M, Cooper D, Carrara H, et al. Limited Pap screening associated with reduced risk of cervical cancer in South Africa. Int J Epidemiol 2003;32:573-577. [http://dx.doi.org/10.1093/ije/dyg081;

(10.) Sawaya G, Kerlikowske K, Lee N, Gildengorin G, Washington A. Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol 2000;96(2):219-223.

(11.) National Health and Medical Research. Guidelines for the Management of Women with Screen Detected Abnormalities. Cranberra: AGPS, 1994.

(12.) Sawaya GF, Chirenje MZ, Magure MT, et al Effect of diaphragm and lubricant gel provision on human papillomavirus infection among women provided with condoms: A randomized controlled trial. Obstet Gynecol 2008;112(5):990-997.

(13.) Bleeker M, Berkhof J, Hogewoning C, et al. HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions. Br J Cancer 2005;92:1388-1392. [http://dx.doi.org/10.1038/sj.bjc.6602524;

(14.) Richardson H, Abrahamowicz M, Tellier PP, et al. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 2005;14:1149-1156. [http://dx.doi.org/10.1158/1055-9965. EPI-04-0230;

(15.) Shields TS, Brinton LA, Burk RD, et al. A case-control study of risk factors for invasive cervical cancer among US women exposed to oncogenic types of human papillomavirus. Cancer Epidemiol Biomarkers Prev 2004;13(10):1574-1582.

Y Adam, J A McIntyre, G de Bruyn Department of Obstetrics and Gynaecology, Chris Hani Baragwanath Academic Hospital and University of the Witwatersrand, Johannesburg

Y Adam, BSc, MB BCh, FCOG (SA), MSc (Epidemiology and Biostatistics) Anova Health Institute, Johannesburg and School of Public Health, Faculty of Health Sciences, University of Cape Town J A McIntyre, MB ChB, FRCOG

Perinatal HIV Research Unit, Chris Hani Baragwanath Academic Hospital and the University of the Witwatersrand, Johannesburg G de Bruyn, MB BCh MPH

Corresponding author: Y Adam (yasminadam@gmail.com)
Table 1. Cytological findings at follow-up Pap smear

              Normal        Inadequate
              (at entry)    (at entry)    Total
              n (%)         n (%)         n (%)

Normal        460 (85.98)   177 (81.19)   637 (84.59)
LSIL          39 (7.29)     13 (5.96)     52 (6.91)
ASCUS         18 (3.36)     11 (5.05)     29 (3.85)
HSIL          2 (0.37)      1 (0.46)      3 (0.40)
Inadequate    16 (2.99)     16 (7.34)     32 (4.2)
Total, N      535           218           753

LSIL = low-grade squamous intra-epithelial lesion; ASCUS = atypical
squamous cells of undetermined significance; HSIL = high-grade
squamous intra-epithelial lesion.

Table 2. A description and comparison of barrier contraception (N=753)

                       Abnormal cytology   Normal cytology
                       N=84 (11.16%)       N=669 (88.84%)
                       n (%)               n (%)

Randomised to the      53 (63.10)          335 (50.07)
intervention arm
(diaphragm)

  n=388 (51.53%)

Randomised to the      31 (36.90)          334 (49.93)
control arm

  n=365 (48.47%)

Condoms used at last   46 (64.79)          392 (72.46)
vaginal sex

  n=438 (71.57%)

Ever used condoms      64 (76.19)          522 (78.03)

  n=586 (77.82%)

Current condom use     53 (63.10)          453 (67.71)
(at baseline)

  n=506 (67.20%)

Female condoms used    4 (5.63)            23 (4.25)
at last intercourse

  n=27 (4.41%)

                             p-value

Randomised to the      0.02 ([chi square])
intervention arm
(diaphragm)

  n=388 (51.53%)

Randomised to the
control arm

  n=365 (48.47%)

Condoms used at last   0.18 ([chi square])
vaginal sex

  n=438 (71.57%)

Ever used condoms      0.70 ([chi square])

  n=586 (77.82%)

Current condom use     0.40 ([chi square])
(at baseline)

  n=506 (67.20%)

Female condoms used    0.54 *
at last intercourse

  n=27 (4.41%)

* Fisher's exact used when there were <5 observations in a cell.

Table 3. Description and comparison of symptoms and tests which
are suggestive of a sexually transmitted disease (N=753)

                                 Abnormal cytology
                                 N=84 (11.16%)
                                 n (%)

Age at first intercourse         Mean 17.32 (SD [+ or -] 1.78)

  Mean 17.58 (SD [+ or -]2.12)

  Range 11 - 27

Sex in exchange for money        4 (4.76%)

  n=17 (2.26%)

Number of male partners          Mean 4.85 (SD [+ or -]3.40)

  Mean 4.02 (SD [+ or -]2.90)

  Range 1 - 26

Average sex in the               Mean 9.46 (SD [+ or -]4.96)
preceding 3 months:

  Mean 9.46 (SD [+ or -]5.12)    Median 8 (IQR 4 - 12)

  Range 3 - 40

                                 Normal cytology
                                 N=669 (88.84%)
                                 n (%)

Age at first intercourse         Mean 17.61 (SD [+ or -]2.15)

  Mean 17.58 (SD [+ or -]2.12)

  Range 11 - 27

Sex in exchange for money        13 (1.94%)

  n=17 (2.26%)

Number of male partners          Mean 3.84 (SD [+ or -]2.73)

  Mean 4.02 (SD [+ or -]2.90)

  Range 1 - 26

Average sex in the               Mean 9.46 (SD [+ or -]4.96)
preceding 3 months:

  Mean 9.46 (SD [+ or -]5.12)    Median 7 (IQR 5 - 12)

  Range 3 - 40

                                 p-value

Age at first intercourse         0.24 *

  Mean 17.58 (SD [+ or -]2.12)   0.18 ([double dagger])

  Range 11 - 27

Sex in exchange for money        0.11 ([section])

  n=17 (2.26%)

Number of male partners          0.00 *

  Mean 4.02 (SD [+ or -]2.90)

  Range 1 - 26

Average sex in the               1 *
preceding 3 months:

  Mean 9.46 (SD [+ or -]5.12)    0.39 ([dagger])

  Range 3 - 40

* t-test; ([dagger]) Wilcoxon ranksum; ([double dagger]) t-test
(unequal variances); ([section]) Fisher's exact.

Table 4. A description and comparison of symptoms and tests
which are suggestive of an STI (N=753)

                                 Abnormal cytology
                                 N=84 (11.16%)
                                 n (%)

Have you ever been treated       22 (26.51%)
for an STI?

  153 (20.51%)
  n=746

Number of times treated          Mean 1.91 (SD [+ or -]1.95)
  Mean 1.26 (SD [+ or -]0.89)

Symptoms suggestive of an STI    15 (18.07)
  n=68 (9.12%)

Abnormal bleeding in             1 (1.20)
the last 3 months
  n=22 (2.95%)

Vaginal discharge on history     11 (13.25)
in the last 3 months
  n=37 (4.96%)

Chlamydia at entry               5 (5.95)
  n=41 (3.44%)

Gonorrhea at entry               1 (1.19)
  n=7 (0.93%)

Trichomonas                      1 (1.19)
  n=12 (1.59%)

WR positive                      1 (5)
  n=10 (4.55%)

HSV at entry                     56 (66.67)
  n=482 (64.01%)

Incident HIV                     2 (2.38)
  n=10 (1.33%)

                                 Normal cytology
                                 N=669 (88.84%)
                                 n (%)

Have you ever been treated       131 (19.76%)
for an STI?

  153 (20.51%)
  n=746

Number of times treated          Mean 1.15 (SD [+ or -]0.49)
  Mean 1.26 (SD [+ or -]0.89)

Symptoms suggestive of an STI    53 (7.99)
  n=68 (9.12%)

Abnormal bleeding in             21 (3.17)
the last 3 months
  n=22 (2.95%)

Vaginal discharge on history     26 (3.92)
in the last 3 months
  n=37 (4.96%)

Chlamydia at entry               36 (5.38)
  n=41 (3.44%)

Gonorrhea at entry               6 (0.90)
  n=7 (0.93%)

Trichomonas                      11 (1.64)
  n=12 (1.59%)

WR positive                      9(4.5)
  n=10 (4.55%)

HSV at entry                     426 (63.68)
  n=482 (64.01%)

Incident HIV                     8 (1.20)
  n=10 (1.33%)

                                 p-value

Have you ever been treated       0.15 ([chi square])
for an STI?

  153 (20.51%)
  n=746

Number of times treated          0.00 *
  Mean 1.26 (SD [+ or -]0.89)

Symptoms suggestive of an STI    0.00 ([chi square])
  n=68 (9.12%)

Abnormal bleeding in             0.28 ([dagger])
the last 3 months
  n=22 (2.95%)

Vaginal discharge on history     0.00 ([chi square])
in the last 3 months
  n=37 (4.96%)

Chlamydia at entry               0.84 ([dagger])
  n=41 (3.44%)

Gonorrhea at entry               0.57 ([dagger])
  n=7 (0.93%)

Trichomonas                      1 ([dagger])
  n=12 (1.59%)

WR positive                      1 ([dagger])
  n=10 (4.55%)

HSV at entry                     0.81 ([chi square])
  n=482 (64.01%)

Incident HIV                     0.20 ([dagger])
  n=10 (1.33%)

* t-test ([dagger]) Fisher's exact

Table 5. Univariate and multivariate analysis

                                         Univariate analysis

                                     OR     95% CI        p-value

Age                                  0.98   0.95 - 1.01    0.17

Contraception-barrier

  Used a male condom at the last     0.70   0.41 - 1.18    0.18
  vaginal sexual intercourse

  Condoms as opposed to diaphragm    0.59   0.37 - 0.94    0.03

Pregnancy history

  Had an ectopic pregnancy           3.31   1.01 - 10.79   0.05

Sexual history

  Coitarche at age [less than or     0.52   0.23 - 1.17    0.11
  equal to]19 years v. >19 years

  Number of male partners            1.10   1.03 - 1.18    0.00

STI

  Treated for a STI                  1.46   0.87 - 2.47    0.15

  Number of times treated            2.43   1.21 - 4.89    0.01

  History of vaginal discharge       3.74   1.78 - 7.89    0.00

HIV                                  2.08   0.43 - 10.00   0.36

                                         Multivariate analysis

                                     OR      95% CI        p-value

Age                                  0.97    0.89 - 1.05    0.42

Contraception-barrier

  Used a male condom at the last     0.75    0.40 - 1.39    0.36
  vaginal sexual intercourse

  Condoms as opposed to diaphragm    0.51    0.27 - 0.97    0.04

Pregnancy history

  Had an ectopic pregnancy           9.25    1.78 - 48.02   0.01

Sexual history

  Coitarche at age [less than or     0.83    0.32 - 2.14    0.70
  equal to]19 years v. >19 years

  Number of male partners            1.12    1.03 - 1.22    0.01

STI

  Treated for a STI                  0.98    0.50 - 1.90    0.95

  Number of times treated            6.59    1.54 - 28.19   0.01

  History of vaginal discharge       13.95   1.18 - 164.5   0.04

HIV                                  6.58    1.14 - 38.16   0.04
Gale Copyright: Copyright 2013 Gale, Cengage Learning. All rights reserved.